發送短信 : Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

 __   _      ___       _____   _    _    __   __  
| || | ||   / _ \\    / ___// | || | ||  \ \\/ // 
| '--' ||  / //\ \\   \___ \\ | || | ||   \   //  
| .--. || |  ___  ||  /    // | \\_/ ||   / . \\  
|_|| |_|| |_||  |_|| /____//   \____//   /_//\_\\ 
`-`  `-`  `-`   `-` `-----`     `---`    `-`  --`